SC 410

Drug Profile

SC 410

Alternative Names: SC410

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator Sancilio & Company
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-alcoholic fatty liver disease

Most Recent Events

  • 22 Jan 2016 Sancilio & Company plans to submit an IND application with the US FDA for Non-alcoholic fatty liver disease in late 2016 (Sancilio form S-1; December 2015)
  • 01 Dec 2014 Preclinical trials in Non-alcoholic fatty liver disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top